MRTX News and Press, Mirati Therapeutics Inc. From 08/11/23

Mirati Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO , Aug. 11, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology c...

2023-08-10 14:59:33 ET Citi has upgraded its rating for Mirati Therapeutics ( NASDAQ: MRTX ) to buy, citing the company's decision to have its founder serve as interim CEO, an improved risk/reward profile, and comparatively low valuation. Citi said that it believes the stock's v...

2023-08-10 07:30:00 ET Summary Tango Therapeutics is advancing in cancer treatment with Phase 1/2 clinical trials for TNG908 and TNG462, targeting MTAP-deleted tumors. Tango's stock soared by over 100% following Mirati's announcement on their unique PRMT5 inhibitor, emphasizing po...

Cancer Discovery Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers through Novel Approach to MTA-Cooperative PRMT5 Inhibition PR Newswire The detailed pharmacological and mechanistic characterization of MRTX1719 demonstrates that bloc...

2023-08-09 13:27:46 ET Gainers: Benitec Biopharma ( BNTC ) +81% . Tango Therapeutics ( TNGX ) +77% . Decibel Therapeutics ( DBTX ) +76% . T Stamp ( IDAI ) +50% . Millennium Group International Holdings ( MGIH ) +43% . EBET ( ...

2023-08-09 10:56:05 ET Shares of Mirati Therapeutics (NASDAQ: MRTX) are up more than 27% as of 10:25 a.m. ET. The company released earnings after the markets closed on Tuesday. The healthcare stock is down more than 21% so far this year. Mirati is a biotech company t...

2023-08-09 10:08:11 ET Gainers: Tango Therapeutics ( TNGX ) +137% . Decibel Therapeutics ( DBTX ) +72% . Mirati Therapeutics ( MRTX ) +26% . Azenta ( AZTA ) +25% . Clover Health Investments ( CLOV ) +18 % . Losers: ...

2023-08-09 04:54:27 ET More on Mirati Therapeutics Mirati Therapeutics: EU Rejection Clouds Krazati's Prospects Mirati: The High Stakes Of Krazati's Market Performance Amidst Dwindling Cash (Rating Downgrade) Mirati fails to win EU backing for lung cancer therapy ...

Mirati Therapeutics Announces Pricing of Upsized Public Offering PR Newswire SAN DIEGO , Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a commercial stage biotechnology company, today announced the pricing of an underwritten public offerin...

2023-08-08 20:51:10 ET Mirati Therapeutics, Inc. (MRTX) Q2 2023 Earnings Conference Call August 08, 2023 04:30 PM ET Company Participants Ryan Asay - Vice President-Corporate Affairs Chuck Baum - President, Founder & Interim Chief Executive Officer Alan Sandl...